Skip to main content
OLIPASS CORPORATION logo

OLIPASS CORPORATION — Investor Relations & Filings

Ticker · 244460 ISIN · KR7244460002 KO Professional, scientific and technical activities
Open in API
Filings indexed 505 across all filing types
Latest filing 2025-09-15 Regulatory Filings
Country KR South Korea
Listing KO 244460

About OLIPASS CORPORATION

https://www.olipass.com/front/eng/index…

OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.

Recent filings

Filing Released Lang Actions
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a previous disclosure titled 'Investment Judgment Related Major Management Matters'. It details an extension of a confidentiality period regarding R&D revenue received from Vanda Pharmaceuticals. Since this is a specific regulatory disclosure regarding material management matters and does not fit into categories like financial reports, dividends, or M&A, it is classified as a general Regulatory Filing (RNS).
2025-09-15 Korean
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Material Management Matter' (투자판단 관련 주요경영사항). It details an amendment to a previous disclosure concerning the receipt of research and development funds from Vanda Pharmaceuticals. Since this is a specific regulatory disclosure regarding business operations and contract amendments that does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2025-09-15 Korean
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Material Management Matter' (투자판단 관련 주요경영사항). It details an amendment to a previous disclosure concerning the receipt of research and development funds from Vanda Pharmaceuticals. Since this is a specific regulatory disclosure of a material event (contract amendment/R&D payment update) and does not fit into the other specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2025-09-15 Korean
[기재정정]주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a regulatory filing from a Korean company (Olipass) regarding the 'Resolution to Convene a General Meeting of Shareholders' (주주총회소집결의). It details the agenda for an Extraordinary General Meeting, including items like changes to the articles of incorporation and stock option grants. This type of document is a formal notice to shareholders regarding meeting logistics and agenda items, which falls under Proxy Solicitation & Information Statement (PSI) as it provides the necessary information for shareholders to prepare for the meeting.
2025-09-12 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) for Olipass Corporation. It outlines the meeting date, location, agenda items (such as articles of incorporation changes and stock option grants), and voting procedures. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their participation/votes. According to the provided definitions, this falls under 'Proxy Solicitation & Information Statement'.
2025-09-12 Korean
기타시장안내 (상장폐지 관련 이의신청서 접수)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange regarding the filing of an objection letter by the company 'OliPass' following a decision to delist its shares. It is an official announcement concerning the delisting process, which fits the definition of a delisting announcement.
2025-09-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.